---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039417"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:36:55.090223+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics appoints Gülsen Kama as CFO effective September 11, 2023; Chris Stewart resigns

## Summary
- Kama's base salary set at $460,000/year with 55% target bonus; receives option for 106,000 shares vesting over 4 years.
- Kama also gets a one-time $150,000 signing bonus contingent on one year of continuous employment.
- Stewart's severance includes lump sums equal to six weeks base salary, additional six weeks upon strategic milestone, and six months base salary cash.
- Stewart will consult at $500/hour through November 11, 2023, with equity vesting continuing during consulting period.
- Kama previously served as CFO of Northern Data AG and East Region & Healthcare IT CFO at Quest Diagnostics.

## SEC filing metadata
- accession: 0001140361-23-039417
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036123039417/0001140361-23-039417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036123039417/brhc20057474_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039417
- JSON: https://secwatch.observer/filing/0001140361-23-039417.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039417.txt

## Key facts
- Executive change
  Gülsen Kama was appointed as Chief Financial Officer at Bionano Genomics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036123039417/0001140361-23-039417-index.htm
- Executive change
  Christopher Stewart resigned as Chief Financial Officer at Bionano Genomics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036123039417/0001140361-23-039417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.